Consistently with the notion that estrogen exposure is lower in carriers of the high-activity CYP2C19*17 allele, ultrarapid metabolizers have been shown to present lower incidence of breast cancer, and lower recurrences of hormonal sensitive breast cancer after treatment with tamoxifen [26, 27]. The gene discussed is CYP2C19; the disease is breast carcinoma.